Maxim Group Increases Abeona Therapeutics Inc. (ABEO) Price Target to $8.00
Abeona Therapeutics Inc. (NASDAQ:ABEO) had its target price increased by Maxim Group to $8.00 in a research note issued on Wednesday. Maxim Group’s target price would suggest a potential upside of 21.77% from the company’s current price.
ABEO has been the subject of several other reports. Cantor Fitzgerald started coverage on Abeona Therapeutics in a research report on Wednesday, September 7th. They set a “buy” rating and a $21.00 target price for the company. Zacks Investment Research lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 12th. FBR & Co reaffirmed a “buy” rating and set a $15.00 target price on shares of Abeona Therapeutics in a research report on Friday, August 26th. Finally, Rodman & Renshaw reaffirmed a “buy” rating and set a $17.00 target price on shares of Abeona Therapeutics in a research report on Sunday, August 21st. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Abeona Therapeutics has a consensus rating of “Buy” and a consensus price target of $12.80.
Abeona Therapeutics (NASDAQ:ABEO) traded up 13.67% on Wednesday, reaching $6.57. 1,361,335 shares of the company traded hands. The firm has a 50 day moving average of $4.28 and a 200-day moving average of $3.09. The stock’s market capitalization is $220.39 million. Abeona Therapeutics has a one year low of $2.05 and a one year high of $6.74.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/maxim-group-increases-abeona-therapeutics-inc-abeo-price-target-to-8-00.html
Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.06. Abeona Therapeutics had a negative net margin of 2,177.03% and a negative return on equity of 30.84%. On average, analysts anticipate that Abeona Therapeutics will post ($0.73) EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Sabby Management LLC increased its position in Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock valued at $855,000 after buying an additional 34,108 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 10,082 shares in the last quarter. Royce & Associates LP increased its position in shares of Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock valued at $963,000 after buying an additional 76,678 shares in the last quarter. Finally, BlackRock Fund Advisors increased its position in shares of Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock valued at $774,000 after buying an additional 23,734 shares in the last quarter. Institutional investors own 19.95% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.